Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 4/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15360322 | 0.92 | LMNA (0.43) | POLBKDM4ELMNAKMT2AL3MBTL1 | |
| SCHEMBL16583134 | 0.87 | MAPK1 (0.44) | MAPK1KDM4ELMNAKMT2AL3MBTL1 | |
| SCHEMBL15352008 | 0.85 | ALDH1A1 (0.39) | POLBKDM4ELMNAKMT2AL3MBTL1 | |
| SCHEMBL17583150 | 0.81 | POLB (0.39) | MAPK1POLBKDM4ELMNAKMT2A | |
| SCHEMBL20290536 | 0.80 | SIRT6 (0.41) | MAPK1POLBKDM4EKMT2AGAA | |
| SCHEMBL15352113 | 0.80 | LMNA (0.43) | POLBKDM4ELMNAL3MBTL1SMN1; SMN2 | |
| SCHEMBL30185861 | 0.78 | KDM4E (0.39) | MAPK1POLBKDM4ELMNAKMT2A | |
| SCHEMBL14330661 | 0.78 | KDM4E (0.39) | MAPK1POLBKDM4ELMNAKMT2A | |
| SCHEMBL992080 | 0.77 | MAPK1 (0.50) | MAPK1KDM4ELMNAKMT2AL3MBTL1 | |
| SCHEMBL16590728 | 0.75 | LMNA (0.43) | POLBKDM4ELMNAKMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2841423-B1 | METHOD FOR PRODUCING 5-(DIFLUOROMETHYL)PYRAZINE-2-CARBOXILIC ACID AND PRODUCTION INTERMEDIATE THEREOF | EISAI R&D MAN CO LTD (JP) | 2016-11-30 | — | — | EP | disclosed |
| US-9227942-B2 | Method for producing 5-(difluoromethyl)pyrazine-2-carboxylic acid and production intermediate thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2016-01-05 | — | — | US | disclosed |
| US-20150087836-A1 | METHOD FOR PRODUCING 5-(DIFLUOROMETHYL)PYRAZINE-2-CARBOXILIC ACID AND PRODUCTION INTERMEDIATE THEREOF | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2015-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150087836-A1 | METHOD FOR PRODUCING 5-(DIFLUOROMETHYL)PYRAZINE-2-CARBOXILIC ACID AND PRODUCTION INTERMEDIATE THEREOF | BACE1, BACE2, APP | MAPK1 3767/4885POLB 1608/4885KDM4E 660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.